stockrow
Friday 6 November 2026
Export RYTM’s income statement to Excel — free account
Rhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
112.38
7.36
+7.01%
Follow RYTM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
23.42 | 31.74 | 27.22 | 36.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2,147.15) | (832.15) | (133.79) | (273.97) | |
P/B ratio |
74.74 | 73.95 | 48.10 | 50.02 | |
Price to Tangible BV |
92.23 | 77.64 | 50.18 | 52.01 | |
EV/Sales |
22.27 | 30.36 | 25.65 | 34.61 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(76.46) | (69.15) | (46.62) | (56.77) | |
EV/FCF |
(49.15) | (48.31) | (33.77) | (40.76) | |
Quick Ratio |
2.39 | 3.00 | 3.63 | 3.92 | |
Current Ratio |
2.78 | 3.45 | 4.17 | 4.41 | |
Net Debt/EBITDA |
8.22 | 6.85 | 6.54 | 8.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.59 | 0.59 | 0.52 | 0.44 | |
Operating CF/Net income |
0.07 | 0.18 | 0.78 | 0.52 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (3.50) | |
Interest Coverage |
(8.74) | (10.69) | (11.42) | (10.20) | |
Research and Development Expense of Revenue |
56.96% | 60.95% | 69.41% | 73.41% | |
Selling, General and Administrative Expense of Revenue |
72.46% | 94.66% | 105.79% | 100.40% | |
Intangible Assets out of Total Assets |
0.04 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
27.16% | 36.57% | 38.43% | 33.65% | |
Graham Net Nets |
0.03 | 0.03 | 0.04 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.03%) | (2.80%) | (3.60%) | (2.91%) | |
Free Cash Flow Yield |
(1.94%) | (1.98%) | (2.79%) | (2.32%) | |
Revenue per Share |
1.33 | 1.04 | 0.88 | 0.88 | |
Operating CF per Share |
(0.04) | (0.13) | (0.65) | (0.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.04) | (0.13) | (0.65) | (0.41) | |
Cash per Share |
4.65 | 4.82 | 5.01 | 5.99 | |
Shareholders Equity per Share |
2.92 | 3.17 | 3.50 | 4.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.92 | 3.17 | 3.50 | 4.16 | |
Free Cash Flow |
(3.06) | (9.15) | (44.18) | (26.34) | |
Working Capital |
268.47 | 302.98 | 326.89 | 360.97 | |
Capital Expenditures |
— | — | — | (0.95) | |
Net Current Asset Value |
177.77 | 206.60 | 225.39 | 256.75 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
36.08 | 33.27 | 26.01 | 22.30 | |
Average Payables |
12.16 | 16.07 | 12.11 | 13.14 | |
Average Inventory |
26.65 | 24.69 | 23.98 | 22.25 | |
Average Assets |
475.00 | 405.00 | 414.50 | 436.23 | |
Average Common Equity |
118.39 | 45.54 | 70.93 | 80.40 |
Columns are period end dates · fundamentals updated 5 Nov 2026